← FDA DRUG APPROVALS

FDA NDA · NDA017895

JANIMINE

Sponsor: ABBOTT

APPLICATION
NDA017895
TYPE
NDA
ORIGINAL APPROVAL
1974-11-15
LATEST ACTION
1988-09-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

JANIMINEDiscontinued
IMIPRAMINE HYDROCHLORIDE 25MG · TABLET · ORAL
JANIMINEDiscontinued
IMIPRAMINE HYDROCHLORIDE 50MG · TABLET · ORAL
JANIMINEDiscontinued
IMIPRAMINE HYDROCHLORIDE 10MG · TABLET · ORAL

Approval history

1988-09-12Manufacturing (CMC) · Supplement 12 · priorityAP
1987-12-14Manufacturing (CMC) · Supplement 11 · priorityAP
1984-12-13Labeling · Supplement 10 · priorityAP
1984-03-27Manufacturing (CMC) · Supplement 9 · priorityAP
1983-12-20Labeling · Supplement 8 · priorityAP
1983-07-15Manufacturing (CMC) · Supplement 7 · priorityAP
1981-06-25Manufacturing (CMC) · Supplement 5 · priorityAP
1977-04-08Labeling · Supplement 4 · priorityAP
1974-11-15Type 6 - New Indication (no longer used) · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →